Colon Cancer |
Cholangiocarcinoma |
Clinical Trial: Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
This study is no longer recruiting patients.
|
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of intravenous infusion or intrahepatic infusion of fluorouracil and leucovorin in treating patients with colorectal cancer metastatic to the liver.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| recurrent colon cancer Stage IV rectal cancer adenocarcinoma of the rectum recurrent rectal cancer childhood gastrointestinal cancer liver metastases stage IV colon cancer adenocarcinoma of the colon | Drug: fluorouracil Drug: leucovorin calcium | Phase III |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Colorectal Cancer; Digestive Diseases; Liver Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase III Randomized Study of Intravenous vs Intrahepatic Arterial Infusion of 5-FU/CF for Colorectal Cancer Metastatic to the Liver
Study start: December 1994
OBJECTIVES: I. Compare the survival and response rates of patients with colorectal liver metastases treated with intravenous vs. intrahepatic arterial infusion of fluorouracil/leucovorin. II. Assess the effect of these 2 treatments on symptoms and quality of life of these patients.
PROTOCOL OUTLINE: Randomized study. Patients randomized to Arm II should have a preoperative hepatic angiography; at laparotomy, an intrahepatic arterial catheter is fused into the gastroduodenal artery to establish an infusion of both lobes of the liver. Arm I: Single-Agent Chemotherapy with Drug Modulation. Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, CF, NSC-3590. Intravenous infusion. Arm II: Single-Agent Chemotherapy with Drug Modulation. 5-FU; with CF. Intrahepatic arterial infusion.
PROJECTED ACCRUAL: 312 patients are expected to be randomized within 3-4 years.
Eligibility
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Histologically confirmed adenocarcinoma of the colon or rectum with metastases confined to the liver and not amenable to surgery
--Prior/Concurrent Therapy--
- No prior fluorouracil (5-FU) for advanced disease; More than 6 months since adjuvant 5-FU (e.g., in AXIS or QUASAR studies)
--Patient Characteristics--
- Age: Any age
- Performance status: WHO 0-2
- Life expectancy: More than 3 months
- Hematopoietic: WBC at least 3,000/mm3; Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3
- Hepatic: Bilirubin less than 3.5 mg/dL (50 micromoles/liter)
- Renal: Not specified
- Cardiovascular: No uncontrolled heart disease (e.g., congestive heart failure, angina)
- Other: No uncontrolled infection; No other uncontrolled medical illness
Location Information
United Kingdom, England
University Birmingham, Birmingham, England, B15 2TT, United Kingdom
David J. Kerr, Study Chair, Medical Research Council
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: May 2004
Last Updated: October 13, 2004
Record first received: November 1, 1999
ClinicalTrials.gov Identifier: NCT00002692
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


